Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg
Ozempic® (semaglutide) injection has emerged as a promising therapy. Developed by Novo Nordisk, Ozempic® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus. With its effectiveness, convenience, and potential to revolutionize diabetes care, Ozempic In Dubai has garnered significant attention in the medical community.
No Products
This company hasn't selected any exports or imports yet.